Role of peptidylarginine deiminase 2 (PAD2) in mammary carcinoma cell migration by Horibata, Sachi et al.
University of Massachusetts Medical School 
eScholarship@UMMS 
Thompson Lab Publications Biochemistry and Molecular Pharmacology 
2017-05-26 
Role of peptidylarginine deiminase 2 (PAD2) in mammary 




Let us know how access to this document benefits you. 
Follow this and additional works at: https://escholarship.umassmed.edu/thompson 
 Part of the Biochemistry Commons, Cancer Biology Commons, Enzymes and Coenzymes Commons, 
Medicinal-Pharmaceutical Chemistry Commons, and the Therapeutics Commons 
Repository Citation 
Horibata S, Rogers KE, Sadegh D, Anguish LJ, McElwee JL, Shah P, Thompson PR, Coonrod SA. (2017). 
Role of peptidylarginine deiminase 2 (PAD2) in mammary carcinoma cell migration. Thompson Lab 
Publications. https://doi.org/10.1186/s12885-017-3354-x. Retrieved from 
https://escholarship.umassmed.edu/thompson/113 
Creative Commons License 
This work is licensed under a Creative Commons Attribution 4.0 License. 
This material is brought to you by eScholarship@UMMS. It has been accepted for inclusion in Thompson Lab 
Publications by an authorized administrator of eScholarship@UMMS. For more information, please contact 
Lisa.Palmer@umassmed.edu. 
RESEARCH ARTICLE Open Access
Role of peptidylarginine deiminase 2
(PAD2) in mammary carcinoma cell
migration
Sachi Horibata1,2, Katherine E. Rogers1, David Sadegh1, Lynne J. Anguish1, John L. McElwee1, Pragya Shah1,
Paul R. Thompson3 and Scott A. Coonrod1*
Abstract
Background: Penetration of the mammary gland basement membrane by cancer cells is a crucial first step in tumor
invasion. Using a mouse model of ductal carcinoma in situ, we previously found that inhibition of peptidylarginine
deiminase 2 (PAD2, aka PADI2) activity appears to maintain basement membrane integrity in xenograft tumors. The
goal of this investigation was to gain insight into the mechanisms by which PAD2 mediates this process.
Methods: For our study, we modulated PAD2 activity in mammary ductal carcinoma cells by lentiviral shRNA-
mediated depletion, lentiviral-mediated PAD2 overexpression, or PAD inhibition and explored the effects of these
treatments on changes in cell migration and cell morphology. We also used these PAD2-modulated cells to test
whether PAD2 may be required for EGF-induced cell migration. To determine how PAD2 might promote tumor cell
migration in vivo, we tested the effects of PAD2 inhibition on the expression of several cell migration mediators in
MCF10DCIS.com xenograft tumors. In addition, we tested the effect of PAD2 inhibition on EGF-induced ductal invasion
and elongation in primary mouse mammary organoids. Lastly, using a transgenic mouse model, we investigated the
effects of PAD2 overexpression on mammary gland development.
Results: Our results indicate that PAD2 depletion or inhibition suppresses cell migration and alters the morphology of
MCF10DCIS.com cells. In addition, we found that PAD2 depletion suppresses the expression of the cytoskeletal
regulatory proteins RhoA, Rac1, and Cdc42 and also promotes a mesenchymal to epithelial-like transition in tumor cells
with an associated increase in the cell adhesion marker, E-cadherin. Our mammary gland organoid study found that
inhibition of PAD2 activity suppresses EGF-induced ductal invasion. In vivo, we found that PAD2 overexpression causes
hyperbranching in the developing mammary gland.
Conclusion: Together, these results suggest that PAD2 plays a critical role in breast cancer cell migration. Our findings
that EGF treatment increases protein citrullination and that PAD2 inhibition blocks EGF-induced cell migration suggest
that PAD2 likely functions within the EGF signaling pathway to mediate cell migration.
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Background
Cell migration is a highly complex process that is involved
in various biological processes ranging from embryonic
development to the immune response [1–3]. Moreover, it is
often dysregulated in cancer and plays an important role in
metastasis and invasion [4, 5]. To migrate, cells modify
their shape and stiffness by becoming polarized and
elongated [6], forming protrusions and extensions which
branch outwards to define the leading edge [7, 8]. These
protrusions are functionally diverse and include lamelipo-
dia, filopodia, spikes (early filopods), pseudopods, ruffles
(early pseudopods), or invadopods [9, 10]. While the newly
formed leading edge establishes the formation of new
adhesion sites [11], changes in the trailing edge are also re-
quired for cells to move forward. For example, cells must
lose contact with the previous adhesion site at the trailing
edge and, when contraction of the actomyosin cytoskeleton
occurs, the trailing edge must generate sufficient traction
force to allow the cell body to move forward [4, 12].
Given the critical role of cell migration in biological
processes, it is not surprising that its dysregulation is asso-
ciated with cancer progression. In normal breasts, there
are two distinct cell layers that line the mammary duct. A
basal layer of myoepithelial cells is bounded by a basement
membrane that separates the mammary gland epithelium
from the surrounding stromal tissues. Superficial to the
basal layer are the luminal epithelial cells [13]. In luminal
breast cancers, the luminal epithelial cells proliferate
uncontrollably and fill the mammary gland, thereby
disrupting tissue architecture and eventually breaking the
myoepithelial basement membrane. Once free from the
basement membrane, the cancer cells can then migrate
out from the mammary gland, resulting in invasive breast
cancer [14]. It is thought that ductal carcinoma in situ
(DCIS) lesions become invasive when the tumor cells
undergo an epithelial-to-mesenchymal transition (EMT),
thus facilitating their migration across the basement mem-
brane [15, 16]. Cancer cells undergoing EMT frequently
downregulate E-cadherin leading to a loss of epithelial cell
polarity and adhesiveness [17] and these tumor cells also
acquire mesenchymal cell characteristics that include in-
creased cell motility and invasiveness. Multiple signaling
pathways have been found to regulate EMT including
TGF-β, PI3K/AKT, and the transcription factors Snail,
Slug, and Smad [16, 18–20].
Initiation of cell migration is often mediated by growth
factors, chemokines and/or by components of the extracellu-
lar matrix (ECM) [4]. Epidermal growth factor (EGF) is a
major inducer of cell migration in breast cancer cells and
functions in this capacity by activating a phosphatidyl-inositol
3-kinase (PI3K) signal transduction cascade which then leads
to the activation of the Rho family of small GTPases (includ-
ing Rho, Rac, and Cdc42) [7, 10, 21–23]. These GTPases are
regulated in a very specific manner in order to coordinate the
proper movement of the cellular actin cytoskeleton [24]. Rac
localizes to the leading edge where it promotes the formation
of cell protrusions via coordination of actin polymerization.
On the other hand, Rho localizes to the trailing edge where it
helps coordinate the contraction of the actin cytoskeleton.
Lastly, Cdc42 is involved in orienting the microtubule assem-
bly in the direction of cell movement. The identity of other
molecules that modulate Rho family-mediated cell migration
remains unclear.
Peptidylarginine deiminases (PADs) are a family of
calcium-dependent enzymes that post-translationally
convert arginine residues into neutrally charged citrulline.
This activity, referred to as citrullination or deimination,
can alter the target protein’s tertiary structure or the
substrate-binding of the target protein [25]. There are five
PAD isozymes, PAD1–4, and 6, with each having a unique
tissue distribution. Previously, we found that peptidylargi-
nine deiminase 4 (PAD4) suppressed breast cancer cell mi-
gration via its role in modulating EMT [26]. Tanikawa et al.
have also shown that ectopic expression of PAD4 results in
inhibition of tumor cell growth [27]. Aside from PAD4, we
also found that PAD2 localizes to mammary tissues and is
dysregulated in breast cancer [28–31]. Unlike PAD4, we ob-
served that PAD2 seems to be involved in promoting breast
cancer progression [30, 32]. Using the pan-PAD inhibitor,
Cl-Amidine (first generation inhibitor) [33–35], we recently
found that the mammary duct basement membrane of
MCF10DCIS.com xenograft tumor restores its basement
membrane integrity [30]. To build upon on our previous
findings, we used Cl-Amidine, as well as a more potent
PAD inhibitor, BB-Cl-Amidine (second generation inhibi-
tor) [36], to investigate the potential mechanisms by which
PAD2 mediates tumor cell migration across the basement
membrane, thereby enhancing tumor cell invasion.
Methods
Materials
The following antibodies were used: anti-PAD2 (12110–1-
AP, Proteintech), anti-E-cadherin (ab1518, Abcam), anti-
RhoA (2117, Cell Signaling), anti-Rac1 (05–389, Millipore),
anti-Cdc42 (07–1466, Millipore), anti-pan-Citrulline (07–
377, Millipore; ab6464, Abcam), and anti-β-actin (ab8227,
Abcam) antibodies. PAD inhibitors, Cl-Amidine [33, 35]
and BB-Cl-Amidine [36], were generous gifts from Dr. Paul
Thompson (University of Massachusetts Medical School).
Cell culture and lentivirus generation
Human comedo ductal carcinoma in situ cells
(MCF10DCIS.com) were obtained from Dr. Fred Miller
(Barbara Ann Karmanos Cancer Institute, Detroit, MI,
USA). Generation of MCF10DCIS.com cells has been de-
scribed [37]. Cells were cultured in DMEM/F-12 medium
containing 5% horse serum (HS) and 1% penicillin
streptomycin (P/S). To generate the PADI2 knockdown and
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control cell lines, MCF10DCIS.com cells were stably
transduced with lentivirus expressing shRNA (Mission
shRNA from Sigma) for PADI2 (TRCN0000051447 –
NM_007365.1-995s1c1) or scrambled non-mammalian
shRNA control (SHC002). Lentivirus was prepared and
transduced as previously described in Campeau et al. using
3rd generation lentiviral packaging/envelope vectors (pLP1-
pMDLg/pRRE [12,251, Addgene], pLP2-pRSV-Rev. [12,253,
Addgene], and pVSV-G-pMD2.G [12,259, Addgene]) [38].
Selection of the stable clones was accomplished via treatment
with 2 μg/ml of puromycin for at least 2 weeks. Scrambled
control shRNA and PADI2-shRNA of MCF10DCIS.com cells
were grown in the described MCF10DCIS.com media with
addition of 2 μg/ml of puromycin.
Immunoblot assay
Whole cell lysates (50 μg of protein per lane) were resolved
by SDS-PAGE followed by transfer to PVDF membrane.
The membranes were blocked in either 5% milk (for anti-
E-cadherin, anti-RhoA, anti-Rac1, anti-Cdc42, and anti-β-
actin) or 3% BSA (for anti-PAD2) at room temperature and
were incubated overnight with primary antibodies diluted
in TBST at 4 °C using the following antibody concentra-
tions: anti-PAD2 (1:1000), anti-E-cadherin (1:1000), anti-
RhoA (1:1000), anti-Rac1 (1:1000), and anti-Cdc42 (1:1000)
antibodies. To ensure equal loading, membranes were
probed with anti-β-actin (1:6000) antibody. The primary
antibodies were detected with HRP-conjugated secondary
antibodies and were exposed to ECL reagents.
RNA isolation and quantitative real-time PCR
RNA was purified using RNeasy Kit (Qiagen) and reverse-
transcribed using High Capacity RNA-to-cDNA kit
(Applied Biosystems) according to the manufacturers’
protocols. Real-time quantitative PCR analysis was per-
formed using the following primers [39, 40]: PAD2 (PADI2)
Forward (5′-TCTCAGGCCTGGTCTCCA-3′) and Reverse
(5′- AAGATGGGAGTCAGGGGAAT-3′); E-cadherin (CD
H1) Forward (5′- TGGAGGAATTCTTGCTTTGC-3′)
and Reverse (5′- CGCTCTCCTCCGAAGAAAC-3′); β-
actin (ACTB) Forward (5′- CCAACCGCGAGAAGATGA-
3′) and Reverse (5′- CCAGAGGCGTACAGGGATAG-3′);
RhoA (RHOA) Forward (5′-CCAAATGTGCCCATCATC
CTAGTTG-3′) and Reverse (5′-TCCGTCTTTGGTCTTT
GCTGAACAC-3′); Rac1 (RAC1) Forward (5′-CAATGCG
TTCCCTGGAGAGTACA-3′) and Reverse (5′-ACGTCT
GTTTGCGGGTAGGAGAG-3′); Cdc42 (CDC42) Forward
(5′-TAACTCACCACTGTCCAAAGACTCC-3′) and Re-
verse (5′-CCTCATCAAACACATTCTTCAGACC-3′) and
Power SYBR Green PCR Master Mix (Applied Bioystems).
The samples were normalized to β-actin and three bio-
logical replicates were performed. The Applied Biosystems
StepOne Real-Time PCR System was used to perform this
assay.
Immunofluorescence (IF) and immunohistochemistry (IHC)
Cells were fixed with 4% paraformaldehyde for 15 min and
were permeabilized and blocked with PBS containing 0.1%
Triton X-100 and 10% BSA. Cells were incubated overnight
with indicated primary antibodies in 1:100 dilutions at 4 °C.
Cells were rinsed with PBS and were incubated with sec-
ondary antibody diluted in PBS containing DAPI (1:50,000)
for 1 h at room temperature. Cells were washed with PBS
and mounted using ProLong antifade mounting reagent
(P36934; Life Technologies). IF and IHC of tissue sections
were prepared using a standard protocol as described previ-
ously [41].
Cell migration (scratch or wound healing assays)
MCF10DCIS.com cells expressing scrambled shRNA or
PADI2-shRNA were grown to confluence in their regular
selection medium (DMEM/F-12 medium containing 5%
HS, 1% P/S, and 2 μg/ml). A wound was generated on a
cover slip using a pipette tip and the culture media was
changed to remove detached cells. Eighteen or twenty-
four hours later, the cells were fixed for 12 min with 4%
paraformaldehyde, washed with PBS, and visualized by light
microscopy. When examining the effect of EGF or BB-Cl-
Amidine on cell migration, the MCF10DCIS.com cells were
first grown in their regular selection media for plating and
then serum starved for 24 h. Once the cells were confluent,
a wound was struck and the detached cells were removed.
DMEM/F-12 containing the following treatments were
added: control (DMSO), EGF (100 ng/ml), BB-Cl-Amidine
(0.5 μM), or both EGF (100 ng/ml) and BB-Cl-Amidine
(0.5 μM). For live cell-imaging of cell migration, after the
wound was struck and the detached cells were removed,
cells were imaged every 10 min over the duration of 24 h.
Live cell imaging to track single or multi cell migration assay
Scrambled shRNA and PADI2-shRNA MCF10DCIS.com
cells were plated lightly (~10–20% confluence) in tissue
culture flask and cultured overnight in cell culture incuba-
tor. Once the cells adhered to the bottom of the flask, the
flask containing the cells was transferred to the Zeiss Axio
Observer inverted microscope with built-in incubator.
The Axiovision software was used to image the cells every
10 min for the duration of 15 or 19 h. For the single cell
migration assay, 20 cells per group (n = 20) were moni-
tored using the Tracking Tool™ Pro v2.0.
Generation of MCF10DCIS.Com xenograft mice
MCF10DCIS.com xenograft mice were generated and
treated with PBS or Cl-Amidine (50 mg/kg/day) using the
protocol described previously [30]. In here, Cl-Amidine
was used as we have optimized the use of Cl-Amidine for
in vivo studies.
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Mammary branching in wild-type and PAD2-
overexpressing mice
Wild type (FVB) and PAD2-overexpressing (MMTV-
PAD2) 8 week old female mice were used to examine differ-
ences in mammary gland development under the influence
of increased PAD2 expression in vivo. The derivation of
MMTV-PAD2 mice has been described previously [39].
The estrous cycle of mice was determined by vaginal
flushes and cytological examination and only those in dies-
trous were used for mammary harvest. Mice were sacrificed
by CO2 inhalation and both mammary glands were re-
moved as described by Plante et al. [42]. One gland was
fixed in 10% neutral buffered formalin, processed and em-
bedded in paraffin for sectioning. Five micron sections were
stained with hematoxalin and eosin (H&E). The other gland
was fixed in Carnoy’s, stained with carmine alum, and
whole mounted on a slide [42] for measurement of ductal
elongation and alveolar branching. Images using 5× (low
magnification) and 20× (high magnification) objectives of
H&E stained slides were obtained using Axiovision software
on a Zeiss Axio Observer inverted microscope equipped
with an Axiocam color CCD camera. To measure branch-
ing, whole mounts were imaged using 0.8× and 5×
objectives and branching was quantified on images using
ImageJ software by counting the number of branching
points (nodes) in three different and defined areas of 250 X
150 pixels for each tissue sample. Three mice were used for
each group. All experimental procedures using mice
followed recommended guidelines and were approved by
the Institutional Animal Care and Use Committee at
Cornell University.
Ductal invasion and elongation in primary mouse
mammary organoids
Primary mouse mammary organoids were prepared using
the protocol described previously [43]. Eight week old
female mice were sacrificed and their mammary glands
were isolated. Isolated mammary glands were cut and
digested using digestion buffer (2 g/l trypsin, 2 g/l collage-
nase type-iv, 5% [v/v] FBS, 5 μg/ml insulin in DMEM/F12
medium) and incubated on a shaker at 37 °C rotating at
100 rpm for 30 min. Following centrifugation, organoids
were collected from the bottom layer, purified, and
enriched. Organoids were then embedded in matrigel in 8
well-tissue slide chambers. Twenty four hours later, the
samples were treated either with control (DMSO), EGF
(100 ng/ml), EGF (100 ng/ml) + BB-Cl-Amidine (0.5 μM),
or EGF (100 ng/ml) + BB-Cl-Amidine (5 μM). The media
(along with specific treatment doses) were replaced every
3 days. The samples were imaged using Zeiss Axio Obser-
ver inverted microscope after 6 days. Three mice (n = 3)
were used for each treatment. For this particular assay, we
used the next-generation PAD inhibitor, BB-Cl-Amidine,
to test whether PAD2 plays a role in ductal invasion.
Statistical analysis
Statistical analyses were performed using GraphPad
Prism 7. Two groups were compared using two-tailed
Student’s t-test. Sample sizes (n) and statistical signifi-
cance (p-values) are indicated in the Figure Legends.
Results
PAD2 promotes breast cancer cell migration.
To investigate whether PAD2 promotes the migration of
breast cancer cells, we first generated PAD2-depleted
ductal carcinoma in situ (MCF10DCIS.com) cells using
the lentiviral shRNA knockdown system. We confirmed
PADI2-knockdown using quantitative real time PCR and
found that the PAD2-depleted line showed a 97% reduc-
tion in PADI2 mRNA levels when compared to the scram-
bled shRNA cell line (Fig. 1a). Furthermore, immunoblot
and immunofluorescent analyses demonstrated that PAD2
protein levels were also reduced in the PAD2-depleted line
(Fig. 1b and c). Additionally, immunofluorescent analysis
revealed that global levels of citrullinated proteins were re-
duced in the PAD2-depleted line compared to the shRNA
control line (Fig. 1d).
We then tested the effects of PAD2 depletion on cell
migration. Using a wound healing assay, we found that
depletion of PAD2 in MCF10DCIS.com cells inhibited cell
migration, with a 39% reduction in migration in the PAD2-
depleted cells compared to the scrambled shRNA cell line
(Fig. 1e and f). To further test the requirement of PAD2 for
cell invasion, we also investigated the migratory potential of
PAD2 overexpressing MCF10AT cells using the wound
healing assay. Results showed that the migratory potential
of PAD2 overexpressing cells was significantly greater than
that of the control cell line (Additional file 1: Fig. S2).
Interestingly, while quantifying the effects of PAD2 on cell
migration, we observed that the PAD2-depleted cells ap-
peared to be more rounded and tightly packed when com-
pared to the control group, which contained elongated cells
that had frequently appeared to migrate independently into
the wound (Fig. 1f). This observation suggested that PAD2
may be required for early metastatic events where epithelial
cells lose their cell-cell adhesion properties and gain mesen-
chymal properties to become more migratory [17].
We also noted that PAD2 depletion results in reduced
cell proliferation (Additional file 2: Fig. S1). To test whether
the migratory phenotype seen in Fig. 1e was caused by cell
movement and not by cell proliferation, we tracked the
movement of single cells using time-lapse imaging. Results
showed that the PAD2-depleted cells appeared to be
actively dividing; however, the resulting daughter cells
displayed diminished mobility (Fig. 2a). On the other hand,
the shRNA control cells were more migratory and more
dynamic in cell shape.
We further analyzed 20 shRNA control and 20 PAD2-
depleted cells during the course of 19 h and tracked the
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distance travelled away from the point of origin. Strikingly,
most of the PAD2-depleted cells remained stationary, while
the control cells actively migrated away from the point of
origin (Fig. 2b. Using the Tracking Tool™ Pro v2.0, we
quantified the accumulated distance travelled by these cells
and found that the control cells had an average total
distance travelled of 577.0 μm whereas the PAD2-depleted
cells only travelled 139.1 μm (Fig. 2c). Furthermore, we
found the average velocity of the control cells to be 0.5 μm/
min, with the maximum velocity of 1.3 μm/min. In
contrast, the PAD2-depleted cells had an average velocity
of 0.1 μm/min, with the maximum velocity of 0.3 μm/min
(Fig. 2d). This represents a 5-fold reduction in average
velocity in the PAD2-depleted cells compared to the control
cells. These results suggest that PAD2 plays an important
role in regulating cell migration.
Depletion of PAD2 reduces cell protrusion and
downregulates cytoskeletal markers
Cells migrate by altering their shape and stiffness leading
to a polarized and elongated phenotype [6]. We next
tested whether PAD2 depletion alters the morphological
changes that are required for cell migration. We found
that PAD2-depleted cells are less elongated and ap-
peared flatter in shape and more tightly adhered to the
underlying plate (Fig. 3a, white arrow). Additionally, they
were predominantly grouped together rather than iso-
lated as single cells, again, suggesting that these cells
may be more adherent. In contrast, the control cells
were elongated in shape with membrane ruffling at the
edge of the cell protrusions (Fig. 3a, black arrow). In
addition, we observed cells in the control group with up
to five protrusions, thus highlighting their dynamic
Fig. 1 Depletion of PAD2 suppresses cell migration in MCF10DCIS.com cells. a Total RNA was isolated from MCF10DCIS.com cells infected with
scrambled-shRNA and PADI2-shRNA lentiviruses. PADI2 mRNA levels were determined by qRT-PCR (SYBR) using scrambled-shRNA as a reference and
β-actin normalization. Data were analyzed using the 2 -ΔΔ C(t) method and are expressed as the mean ± SD from three independent experiments
(*p < 0.05). b The whole cell lysates of MCF10DCIS.com scrambled-shRNA and PADI2-shRNA cells were immunoblotted with anti-PAD2 antibody.
Anti-β-actin was used as loading control. c Immunofluorescent analysis was performed on scrambled-shRNA and PADI2-shRNA cells probed with
anti-PAD2 antibody, (d) anti-pan-citrulline antibody, and DAPI (nuclei) staining. Scale bars = (C) 50 μm and (D) 25 μm. e Relative average areas of
wound closure from the wound healing assays were calculated using ImageJ and normalizing to scrambled-shRNA (**p < 0.05). f A wound healing
assays were performed on MCF10DCIS.com scrambled-shRNA and PADI2-shRNA cells. The cells were fixed using 4% paraformaldehyde 24 h after
striking the wound (24 h.). The cells were then visualized and imaged using light microscopy to determine the extent of the wound closure. The
widths of the initial wounds are indicated by the lines. The cells were also fixed immediately after striking the wound (0 h.) to indicate the size of the
initial wounds. The images on the right are the enlarged images of the boxed images
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movement. Furthermore, we found enlarged nuclei in
single, isolated PAD2-depleted cells compared to control
cells (Fig. 3a). However, when the cells were grouped or
adhered to other cells, the nuclei of PAD2-depleted cells
were smaller in size.
Next, we tested whether the distinct changes in cell
morphology caused by PAD2 depletion were associated
with cytoskeletal changes. More specifically, we tested
for expression levels of the Rho family of GTPases,
RhoA, Rac1, and Cdc42, as these actin cytoskeleton
markers are known to regulate cell migration [24]. Inter-
estingly, we found that there were significant reductions
in RHOA (38.0%), RAC (32.1%), and CDC42 (30.3%)
transcript levels in the PAD2-depleted cells compared to
the control line (Fig. 3b). Furthermore, immunoblot as-
says confirmed our mRNA findings (Fig. 3c). Collect-
ively, these results suggest that PAD2 promotes cell
migration by modulating the cytoskeletal machinery that
is required for cell motility.
Cell adhesion increases upon PAD2 depletion
Aside from changes in cell morphology, we also observed
changes in the adhesive properties of PAD2-depleted cells.
During the time course of the wound healing assay, we
found that control cells migrated into the wound follow-
ing the initial scratch as described previously. Surprisingly,
in stark contrast, PAD2-depleted cells appeared to initially
contract away from the wound before eventually filling
the vacated area up to the point of the scratch (Fig. 4a).
We next investigated the adhesive properties of single
cells. In PAD2-depleted cells, we found that, over time, in-
dependent cells would adhere to each other eventually
forming cell clusters (Fig. 4b). In contrast, we found that
Fig. 2 Single cell migration is impaired in PAD2 depleted
MCF10DCIS.com cells. a Images of MCF10DCIS.com scrambled-shRNA
and PADI2-shRNA cells taken at times 0, 3, 6, 9, 12, and 15 h at the
same location using a wide-field microscope with a built-in incubation
chamber. The arrow indicates the directional movement of the cells.
Scale bar = 50 μm. b Graphical representation of the movement of
individual cells (n = 20) of scrambled-shRNA and PADI2-shRNA cells in
culture. The line shows the trails of the cell movement and the black
circle shows the final location of the cells. The point of origin is shown
as a white dot. Graphs were generated using Tracking Tool™ Pro v2.0.
c Graph depicts accumulated distance travelled and (d) average
velocity by single scrambled-shRNA and PADI2-shRNA cells
Fig. 3 PAD2 depletion alters the morphology of MCF10DCIS.com cells.
a Representative images of scrambled-shRNA and PADI2-shRNA cells in
culture. Scale bar = 200 μm. The frames on the images to the left are
enlarged on the middle and right images. The middle images show
the morphology of multiple cells that are growing together; images on
the right are the pictures of single cells. The black arrow indicates cell
protrusion and membrane ruffling in the scrambled-shRNA cells. The
white arrow shows the flattened appearance of the cytoplasmic region
of PADI2-shRNA cells. b Total RNA was isolated from scrambled-shRNA
and PADI2-shRNA cells. RHOA, RAC1, and CDC42 mRNA levels were
determined by qRT-PCR (SYBR) using scrambled-shRNA as a reference
and β-actin normalization. Data were analyzed using the 2 -ΔΔ C(t)
method and are expressed as the mean ± SD from five independent
biological replicates with three technical replicates for each biological
replicate (* p < 0.05). c The whole cell lysates of MCF10DCIS.com
scrambled-shRNA and PADI2-shRNA cells were immunoblotted with
RhoA, Rac1, and Cdc42. The blot was also probed with anti-β-actin
as a loading control
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Fig. 4 Enhanced cell-cell adhesion is observed in PADI2-depleted cells. a Scratch assays were performed on scrambled-shRNA and PADI2-shRNA
cells. The cells were visualized and imaged at t = 0, 12, and 24 h, using a wide-field microscope with built-in incubation chamber, to determine
the extent of the wound closure. Widths of initial wounds are indicated by lines. Arrow indicates the directional movement of the migrating cells.
Scale bar = 200 μm. b Images of 2 to 3 scrambled-shRNA and PADI2-shRNA cells were taken at t = 0, 6, and 12 h. Scale bar = 50 μm. c Whole cell
lysates from scrambled-shRNA and PADI2-shRNA cells were immunoblotted with anti-E-cadherin antibody. Anti-β-actin was used as a loading
control. The intensity of the band was measured using ImageJ and was normalized to scrambled-shRNA cells
Fig. 5 Enhanced activity and expression of PAD2 observed in EGF treated MCF10DCIS.com cells. a Scratch assays were performed on
serum-deprived MCF10DCIS.com cells treated without (Untreated) or with EGF. MCF10DCIS.com cells were fixed 24 h after wound striking. Cells
were visualized using light microcopy to determine the extent of wound closure. Serum-deprived MCF10DCIS.com cells were treated without
(Untreated) or with EGF for 1 h prior to immunofluorescent analysis using (b) anti-PAD2 and (c) anti-pan-citrulline antibodies. DAPI was used to
visualize the nucleus. Scale bar = 50 μm
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the control cells would often detach from each other and
migrate independently. These observations suggest that
PAD2 depletion may lead to the upregulation of cell-cell
adhesion molecules, such as E-cadherin. We tested this hy-
pothesis and found that depletion of PAD2 upregulates the
expression of E-cadherin by approximately 5-fold (Fig. 4c).
Together, these findings suggest that depletion of PAD2
suppresses cell migration by promoting the upregulation of
factors that are involved in cell-cell adhesion.
PAD2 may function within the EGF signaling pathway to
regulate cell migration
Given that EGF signaling plays an important role in can-
cer cell polarization and migration, we tested whether
EGF may regulate PAD2 expression and activity and
whether modulation of PAD2 activity may affect EGF-
induced cell migration. We first tested the ability of EGF
to induce cell migration in MCF10DCIS.com cells and
observed robust enhancement of cell migration into the
Fig. 6 BB-Cl-Amidine treatment suppresses cell migration and enhances cell adhesion in MCF10DCIS.com cells. a Scratch assays were performed on
serum-deprived MCF10DCIS.com cells following either no treatment (Untreated) or treatment with EGF, EGF + BB-Cl-Amidine, or with BB-Cl-Amidine alone.
MCF10DCIS.com cells were pre-treated with BB-Cl-Amidine for 23 h and then EGF was added for 1 h. Cells were fixed using 4% paraformaldehyde 24 h
after striking the wound (24 h) and then visualized and imaged using light microscopy to determine the extent of the wound closure. Widths of initial
wounds are indicated by the lines. Cells were fixed immediately after striking the wound (0 h) to indicate the size of the initial wounds. b MCF10DCIS.com
cells were treated either with DMSO or 2 μM BB-Cl-Amidine. One hour after treatment, the cells were imaged using light microscopy. Scale bar = 100 μm.
c Total RNA was isolated from MCF10DCIS.com cells treated with either 0 (DMSO), 1 μM, or 2 μM BB-Cl-Amidine. CDH1 mRNA levels were determined by
qRT-PCR (SYBR) using DMSO treated control cells as a reference and β-actin for normalization. Data were analyzed using the 2 -ΔΔ C(t) method and are
expressed as the mean ± SD from two biological replicates with three technical replicates per biological replicate (* p < 0.05; ** p < 0.005). d Anti-E-
cadherin immunofluorescence staining was performed on serum-deprived MCF10DCIS.com cells following either no treatment (Untreated) or treatment
with EGF, EGF + BB-Cl-Amidine, or with BB-Cl-Amidine alone. MCF10DCIS.com cells were pre-treated with BB-Cl-Amidine for 23 h and then EGF was added
for 1 h. Scale bar = 50 μm
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wound following EGF treatment, thus confirming that
EGF promotes the migration of MCF10DCIS.com cells
(Fig. 5a). We then tested the effect of EGF treatment on
PAD2 expression and activity. Immunofluorescent ana-
lysis found that treatment of MCF10DCIS.com cells with
EGF for 60 min strongly increased PAD2 expression and
activity in these cells (Fig. 5b and c). Interestingly, we
found that EGF treatment resulted in a strong increase
in nuclear PAD2 levels. Together, these suggest that
PAD2 may function within the EGF signaling pathway to
regulate cell migration.
PAD inhibitor, BB-cl-Amidine, suppresses EGF-induced cell
migration
The finding that EGF appears to upregulate PAD2
expression and activity suggested that PAD2 may play a
role in EGF-mediated cell migration. We tested this hy-
pothesis and found that the PAD inhibitor, BB-Cl-Amidine
[36], suppressed EGF-induced migration of MCF10DCIS.-
com cells (Fig. 6a). Interestingly, we also found that when
PAD2 was depleted from cells, EGF treatment did not pro-
mote cell migration (Additional file 3: Fig. S3). Importantly,
we found that BB-Cl-Amidine treatment promoted the
conversion of MCF10DCIS.com cells from an elongated
fibroblast-like migratory phenotype to a more epithelial-like
adherent phenotype which is similar to that of the PAD2-
depleted cells (Fig. 6b).
We then tested whether BB-Cl-Amidine treatment in-
creased the expression of the cell-cell adhesion molecule,
E-cadherin, in MCF10DCIS.com cells. We found that
MCF10DCIS.com cells expressed significantly higher
levels of CDH1 mRNA levels after treatment with BB-Cl-
Amidine (Fig. 6c). Immunofluorescence analysis sup-
ported our qRT-PCR results as we found that E-cadherin
levels appeared to be higher in the BB-Cl-Amidine treated
cells than control cells (Fig. 6d). The increase was also
observed in cells treated with BB-Cl-Amidine in the
presence of EGF. As seen by the DAPI staining, the cells
are in closer proximity to each other in the presence of
BB-Cl-Amidine, further suggesting increased adhesion
when PAD2 activity is inhibited. These results suggest that
one mechanism by which PAD2 activity promotes cell
migration is by downregulating the expression of cell-cell
adhesion molecules in an EGF-dependent manner.
Cl-Amidine treatment increases E-cadherin expression
level in vivo
Previously, we generated a DCIS mouse xenograft model
and tested the effects of the first-generation PAD inhibi-
tor, Cl-Amidine, on tumor growth [30]. In this model
system we consistently found that tumor cells in the Cl-
Amidine treated mice appeared to be less invasive and
that the basement membranes of the ducts within the
treated tumors were more intact (Fig. 7a). Therefore, we
used this model system to test whether PAD inhibition
may suppress tumor cell migration in vivo by promoting
the upregulation of E-cadherin in the tumor cells. We
find that E-cadherin expression appears to be strongly
upregulated in the Cl-Amidine treated group compared
to the control group (Fig. 7b). This suggests that Cl-
Amidine treatment maintained the epithelial-like state of
the cells thereby preventing tumor cells from migrating
out from the mammary duct.
Fig. 7 Cl-Amidine treatment increases E-cadherin expression in MCF10DCIS.com xenograft tumors. a PAS staining of representative mammary tissue
sections of MCF10DCIS.com xenograft mice following either vehicle alone treatment (PBS) or treatment with Cl-Amidine. PAS stained sections were
prepared and imaged using the bright field optics of the Axiophot inverted microscope. Scale bar = 200 μm. b Anti-E-cadherin IF staining of tissue
sections from MCF10DCIS.com xenograft tumors following vehicle alone treatment (PBS) or with Cl-Amidine treatment. Scale bar = 50 μm
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BB-cl-Amidine suppresses ductal invasion in an ex vivo
model of mammary gland development
We next utilized a three-dimensional organoid culture sys-
tem to investigate the effect of PAD2 inhibition on mam-
mary gland morphogenesis. We first induced ductal
morphogenesis using EGF and found a robust increase in
the ductal elongation compared to the control organoid
(Fig. 8a and b). We found that when the organoids were
treated with 0.5 μM BB-Cl-Amidine, there was a striking
reduction in EGF-induced ductal elongation (Fig. 8a and b)
with 5 μM BB-Cl-Amidine completely blocking ductal
elongation (Fig. 8a and b). These results suggest that PAD2
is required for EGF-induced ductal morphogenesis.
PAD2 overexpression enhances mammary branching
EGF and its receptor EGFR are known to play critical roles
in mammary gland morphogenesis during early development
[44–46]. Given the observed links between PAD2 and EGF
signaling, we generated a PAD2 overexpressing mice to test
whether overexpression of PAD2 in the mammary gland
Control EGF
EGF + 0.5 µM BB-Cl-Amidine EGF + 5 µM BB-Cl-Amidine
Scale bar = 50 µm 































































Fig. 8 PAD inhibition suppresses EGF-induced ductal invasion and elongation in primary mouse mammary organoids. a Isolated mammary gland
organoids were cultured in matrigel and were treated with either DMSO (control), EGF (100 ng/ml), EGF (100 ng/ml) + BB-Cl-Amidine (0.5 μM), or
EGF (100 ng/ml) + BB-Cl-Amidine (5 μM). Following 6 days of culture, the samples were imaged using Zeiss Axio Observer inverted microscope.
b The relative area of invasion and elongation (normalized cell area per field) were measured using image J. Samples were normalized to the
control. Data were analyzed using unpaired Student’s t-test and are expressed as the mean ± SEM (*p < 0.01; **p < 0.05; ***P < 0.005)
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may affect mammary gland development. At 8 weeks of age,
we found a 1.7-fold increase in ductal branching in the PAD2
overexpressed mice compared to the wild-type controls (Fig.
9a). Histological evaluation of the mammary tree in adult
females revealed that the epithelial cells are hyperplastic in
nature with poorly formed ductal structures (Fig. 9b). To-
gether, these data suggest that PAD2 plays an important role
in mammary gland morphogenesis during development.
Discussion
Invasion of the of basement membrane by tumor cells rep-
resents a critical step in tumor metastasis. In mouse xeno-
graft models of breast cancer, we have previously shown
that systemic treatment with the PAD inhibitor, Cl-Amidine,
resulted in increased tumoral basement membrane integrity
compared to tumors from mice treated with vehicle alone
[14, 47]. In this study, we show that PAD2 depletion or in-
hibition suppresses tumor cell migration, alters tumor cell
morphology, and suppresses the expression of the cytoskel-
etal regulatory proteins: RhoA, Rac1, and Cdc42. Taken to-
gether, these observations support the hypothesis that PAD2
promotes tumor migration and invasion via its role in
modulating the tumor cell cytoskeleton.
Interestingly, while performing the cell migration assay, we
observed that PAD2-depleted MCF10DCIS cells preferen-
tially adhere to each other, suggesting that PAD2 may be in-
volved in tumor cell migration. In support of this hypothesis,
we found that E-cadherin expression is upregulated in
MCF10DCIS cells following PAD2 depletion. Previously, we
demonstrated that PAD4 plays a role in preventing the EMT
and suppressing the invasive potential of breast cancer cells













































Fig. 9 Mammary gland development in diestrus 8 week old female wild type and MMTV-PAD2 mice. a Graph quantifying number of branches/
field in mammary glands from 8 week old diestrus wild type and MMTV-PAD2 female mice (n = 3). Representative whole mount images (20×)
of mammary gland development in wild type and PAD2 overexpressing mice. Following isolation, mammary fat pads were stained with
carmine-alum for visualization. b Images of formalin-fixed-paraffin embedded mammary gland tissue sections following H&E staining at 5×
(low magnification) and 20× (high magnification). Note the normal appearance of acini in WT mice showing typical epithelial layer and lumen.
In MMTV-PAD2 mice the acini are less organized with apparent infiltration of epithelial cells into the lumen
Horibata et al. BMC Cancer  (2017) 17:378 Page 11 of 14
Thus, it appears that there may be a complex interplay be-
tween these two family members in breast cancer cells with
respect to the EMTand further studies are needed to further
tease out this relationship.
Given that EGF signaling plays an important role in tumor
cell migration, we tested whether there is a link between
PAD2 and EGF. Interestingly, we found that EGF treatment
resulted in a strong increase in nuclear PAD2 levels. We
have previously shown that nuclear PAD2 can regulate gene
expression via citrullination of histone tails at transcription
factor binding sites [31, 48, 49]. Taken together, these results
suggest that the EGF-induced nuclear targeting of PAD2
may lead to PAD2-mediated upregulation of genes involved
in tumor cell migration. In follow up studies, it will be inter-
esting to test whether PAD2-mediated histone citrullination
may regulate EGF-induced gene expression.
Since we observed that PAD2 was upregulated after EGF
treatment, we then tested whether inhibition of PAD2 can
suppress EGF-mediated cell migration. Outcomes from our
in vitro and in vivo studies support this prediction as they
found that BB-Cl-Amidine suppressed EGF-induced tumor
cell migration and invasion. Interestingly, we also observed
upregulation of E-cadherin in our PAD inhibitor-treated
xenograft model. In addition to links between PAD2 and
EGF-mediated tumor cell migration, we also found that
overexpression of PAD2 in FVB mice lead to mammary
gland hyperbranching, thus supporting a role for PAD2 in
mammary tumorigenesis. Taken together, these findings
implicate PAD2 in EGF-mediated mammary gland develop-
ment and tumor cell migration.
From a clinical perspective, many patients with DCIS are
either under- or over- treated because clinicians lack the ap-
propriate molecular markers to help predict recurrence or
progression. Our finding that PAD2 appears to function
within the EGF signaling pathway to modulate DCIS tumor
cell migration suggests that PAD2 and/or citrullination may
have predictive power for identifying aggressive EGFR+ DCIS
lesions. Our finding that the PAD inhibitor, BB-Cl-Amidine,
suppresses EGF-induced tumor cell migration, raises the pos-
sibility that PAD inhibitors could function in therapeutic for-
mulations for treating EGFR-overexpressing breast cancers.
Additionally, it is also possible that PAD inhibitors may syner-
gize with EGFR inhibitors to suppress tumor growth. Future
studies are now being planned to test these hypotheses.
Conclusion
In this study, we performed in vitro and in vivo assays to
test the involvement of PAD2 in the migration of mammary
tumor cells (Fig. 10a). We found that PAD2 depletion or
inhibition greatly impairs cell migration and alters the
morphology of MCF10DCIS.com cells and that PAD2
overexpression in MCF10AT cells promotes cell migration.
In addition, we found that PAD2 depletion suppresses the
expression of Rho GTPases (RhoA, Rac1, and Cdc42),
which are known to be involved in actin-mediated cell
migration. Furthermore, we observed that PAD2 depletion
promotes a mesenchymal to epithelial-like transition in
MCF10DCIS.com cells, with a robust increase seen in the
adhesion marker, E-cadherin. In vivo, we found that treat-
ment of MCF10DCIS.com xenograft tumors with PAD
inhibitors upregulate E-cadherin expression and that EGF-
induced cell migration upregulates PAD2 expression and
activity. We also found that the PAD inhibitor, BB-Cl-
Amidine, inhibits EGF-induced tumor cell migration.
When then observed that PAD2 overexpression in female
FVB mice promotes mammary hyperbranching and
enhanced infiltration of epithelial cells into the alveoli of
the mammary gland, thus supporting the role of PAD2 in
mammary development and tumorigenesis. Furthermore,
our mouse mammary organoid studies showed that we can
enhance ductal invasion via the use of EGF and prevent
invasion using the PAD inhibitor, BB-Cl-Amidine. This sug-
gests that PAD2 likely functions within EGF signaling path-
way to mediate cell migration and invasion. Together, these
findings suggest that PAD2 plays an important role in
mammary tumorigenesis via its role as a mediator of EGF
signaling.
Fig. 10 Schematic diagram illustrating the proposed mechanism of PAD2
in mammary carcinoma cell migration. a In low PAD2 expressing cells,
E-cadherin is upregulated while the Rho family of small GTPases are
downregulated, resulting in increased cell-cell adhesion. On the other hand,
in high PAD2 expressing cells, E-cadherin is downregulated while Rho
family of small GTPases are upregulated, causing increased cell migration.
At the tissue level, this increased cell mobility may result in increased cell
invasion similar to that observed in invasive mammary carcinoma
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Additional files
Additional file 1: Fig. S2. PAD2 overexpression increases the migratory
potential of MCF10AT cells. Relative average areas of wound closure from
the wound healing assays (n = 6) were calculated using ImageJ and
normalized to empty vector controls (* p < 0.05). (PDF 690 kb)
Additional file 2: Fig. S1. Depletion of PAD2 suppresses the ability of
MCF10DCIS.com cells to form foci. Representative image of crystal violet
stained MCF10DCIS.com scrambled-shRNA and PADI2-shRNA cells grown
for 1-week. (PDF 3631 kb)
Additional file 3: Fig. S3. EGF-induced cell migration is inhibited by
BB-Cl-Amidine. Wound healing assays were performed on MCF10DCIS.com
scrambled-shRNA and PADI2-shRNA cells treated with EGF or BB-Cl-Amidine.
The cells were fixed using 4% paraformaldehyde for 32 h after striking the
wound. The cells were then visualized and imaged using light microscopy
to determine the extent of the wound closure. (PDF 15582 kb)
Additional file 4: Supplemental Methods. (DOCX 15 kb)
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